Press releases //

Laboratoire CERBA signs licensing agreement with IntegraGen to commercialize miR-31-3p tumor expression test

IntegraGen SA and Laboratoire CERBA announced the signing of a licensing agreement allowing Laboratoire CERBA to develop and provide  a test based on IntegraGen’s proprietary miR-31-3p biomarker to prescribing clinicians in France, Benelux, Middle East and Africa. Laboratoire CERBA will develop this test to complement its existing portfolio (…)  » 

Press releases //

IntegraGen Reports Revenues for First Half of 2016

IntegraGen today announced its sales for the first half 2016. Sales for IntegraGen’s business totaled € 2.8 million as of June 30, 2016, and increase of 10% compared to the first half of 2015.


Sales of € 2.8 million, a 10% increase vs. H1 2015 Operational result +14% (…)  »